Pardon me, but I'm going to answer in English.
We've heard a lot about Quebec today in the conversation. Thank you very much for the question because it highlights one distinct aspect of Quebec that the rest of Canada should emulate.
The other thing we heard a lot about is that not every patient responds in the same way to the same drug. We need some variety and some choice. Quebec has a mechanism where a doctor can apply to a truly independent scientific review committee that is outside of the health bureaucracy for a drug that the doctor knows the patient needs, whether or not it's been approved by Health Canada and whether or not it's being funded through the existing system.
I come from a rare disease community. PKU, phenylketonuria, is not life-threatening; it's only brain-threatening. I have a son with it who is a responder to the first pharmaceutical, a true and full responder. Every patient with PKU who has received access to that first drug for PKU has been approved through Quebec's unique exception patient program. There will always be outliers.
What we need to achieve and work towards is precision medicine, a molecule that works for the individual given that individual's genetics and biochemistry. We're not all the same. One size does not fit all. It would be a great improvement for national pharmacare, as a concept, to always have that safety valve for the exceptional patient. There are decades of working experience in the province of Quebec that we can all learn valuable lessons from.